Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has scheduled a significant announcement combining two key updates. The company will release topline results from the RADIANT trial of vormatrigine along with its Q2 2025 financial results before market open on August 4, 2025.
The company will host a live webcast at 8:30 AM ET on the same day to discuss these results. Investors can access the webcast through a registration link or the company's website, with a replay available for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRAX gained 0.56%, reflecting a mild positive market reaction. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $1.21B at that time.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025.
The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website. A replay of the webcast will be available on Praxis’ website for 90 days following the event.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors daniel@lifesciadvisors.com 617-430-7576
FAQ
When will Praxis Precision Medicines (PRAX) release its Q2 2025 earnings and RADIANT trial results?
What time is the Praxis Precision Medicines (PRAX) earnings and trial results webcast?
How can investors access the Praxis Precision Medicines (PRAX) RADIANT trial results webcast?
What is the RADIANT trial by Praxis Precision Medicines studying?
How long will the Praxis Precision Medicines (PRAX) webcast replay be available?
